Q3 EPS Estimates for PMN Raised by Brookline Capital Markets

Promis Neurosciences (NASDAQ:PMN) – Equities research analysts at Brookline Capital Markets upped their Q3 2026 EPS estimates for Promis Neurosciences in a research report issued on Friday, August 14th. Brookline Capital Markets analyst F. Ahmed now expects that the company will post earnings per share of ($1.29) for the quarter, up from their previous forecast of ($2.41). Brookline Capital Markets currently has a “Strong-Buy” rating on the stock. The consensus estimate for Promis Neurosciences’ current full-year earnings is ($4.97) per share. Brookline Capital Markets also issued estimates for Promis Neurosciences’ Q4 2026 earnings at ($1.34) EPS, FY2026 earnings at ($5.21) EPS, Q1 2027 earnings at ($1.63) EPS, Q2 2027 earnings at ($1.65) EPS, Q3 2027 earnings at ($1.69) EPS, Q4 2027 earnings at ($1.83) EPS and FY2027 earnings at ($6.83) EPS.

Promis Neurosciences (NASDAQ:PMN) last issued its earnings results on Thursday, August 13th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.10.

A number of other research firms have also recently weighed in on PMN. Chardan Capital set a $20.00 price target on Promis Neurosciences and gave the stock a “buy” rating in a report on Monday, July 27th. HC Wainwright reiterated a “buy” rating on shares of Promis Neurosciences in a research report on Wednesday, July 15th. Roth Capital started coverage on Promis Neurosciences in a report on Tuesday, July 7th. They issued a “buy” rating and a $19.00 target price on the stock. Cantor Fitzgerald assumed coverage on Promis Neurosciences in a research report on Tuesday, June 30th. They issued an “overweight” rating for the company. Finally, Weiss Ratings lowered shares of Promis Neurosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Promis Neurosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.50.

Promis Neurosciences Trading Up 2.2%

PMN stock opened at $14.98 on Wednesday. The firm has a 50 day moving average of $12.96 and a 200-day moving average of $13.69. The company has a market cap of $134.34 million, a price-to-earnings ratio of -1.75 and a beta of -0.23. Promis Neurosciences has a 12-month low of $6.27 and a 12-month high of $27.40.

Hedge Funds Weigh In On Promis Neurosciences

Several large investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC increased its stake in shares of Promis Neurosciences by 168.1% during the 3rd quarter. Citadel Advisors LLC now owns 170,079 shares of the company’s stock valued at $72,000 after acquiring an additional 106,650 shares during the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Promis Neurosciences in the first quarter worth approximately $135,000. ADAR1 Capital Management LLC purchased a new stake in Promis Neurosciences in the first quarter valued at approximately $1,211,000. Armistice Capital LLC grew its holdings in Promis Neurosciences by 39.1% in the third quarter. Armistice Capital LLC now owns 2,974,518 shares of the company’s stock valued at $1,264,000 after purchasing an additional 836,622 shares during the period. Finally, Yu Fan acquired a new position in Promis Neurosciences during the first quarter worth approximately $4,188,000. 50.13% of the stock is currently owned by hedge funds and other institutional investors.

About Promis Neurosciences

Promis Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.